Request Processed

Your registration request has been processed. We will contact you soon.

Register

PrevisionPolicy logo
  • Login
  • Register
  • About
  • Contact Us
« First ‹ Prev … 53 54 55 56 57 58 59 60 61 … Next › Last »

Prevision Policy Clips | Senate Judiciary Pharmaceutical Competition Hearing Will Include PhRMA VP Ulrich, Patient Advocate Mitchell

May 20, 2024

FDA Neurology Office “Very Open” To Accelerated Approval, Director Buracchio Says; CBER Officials See More Intermediate Endpoints For “Underutilized” AA Pathway

May 17, 2024

Prevision Policy Clips | Machine Learning For Shortage Prediction?

May 17, 2024

Rare Pediatric Disease PRV Reauthorization May Come With Strings Attached: New Authority For FDA To Mandate Pediatric Studies Of Orphan Drugs

May 16, 2024

Gene-Edited Cell Therapies Could Benefit From Early Use In Clinic, Researchers Argue; FDA Holding To Careful Characterization First

May 16, 2024

Prevision Policy Clips | BIOSECURE Act Passes House Committee On Oversight & Accountability

May 16, 2024

REMS “Logic Model” Is Next Step Towards Standardizing Risk Management Programs; FDA Outlines Framework As Part Of Effort To “Optimize” REMS

May 15, 2024

Prevision Policy Clips | House Committee To Mark Up Several FDA Bills, Including Potential Changes To Pediatric Cancer Research Program

May 15, 2024

More Is Not Always Better: OCE Foresees Shift To Three-Arm Trials To Measure Add-On Effect; Early-Stage Lung Cancer Is Just The Start, Pazdur Warns

May 14, 2024

BIOSECURE Act Sets 2032 Deadline For Severing Ties With A “Company Of Concern” Under Revised Draft, Five-Year Compliance Period Added For Newly Identified Firms

May 14, 2024

Prevision Policy Clips | Platform Technology Guidance Awaiting OMB Clearance

May 14, 2024

A Peek Inside OCE: FDA Oncology Division Directors See Advantages Of Keeping Sponsor Meetings Virtual, Reflect On Leadership Amid COVID

May 13, 2024

Prevision Policy Clips | Strategic National Stockpile “Mismanagement”: House E&C Republicans Issue Letter

May 13, 2024

CBER Is “Neutral” On CAR-T Manufacturing Strategies, So Long As Quality Is Maintained, Director Marks Says; “Wave” Of Automation Could Bring Down Costs

May 10, 2024

Prevision Policy Clips | Moderna RSV Vaccine Review Delayed By “Administrative Constraints”; FDA Will Miss Deadline

May 10, 2024

Senate Drug Shortage Bill Would Create Medicare Shortage Mitigation Program; Generic Medicaid Inflation Rebate Changes, Add-On Payments Included

May 9, 2024

Prevision Policy Clips | Duke Margolis Drug Shortage Prevention Workshop June 12

May 9, 2024

Advisory Committee Voting Still A Hot Topic: Sen. Manchin Pushes Califf To Keep Votes During Budget Hearing; Avian Flu Is Growing Priority For FDA And Congress

May 8, 2024

Prevision Policy Clips | Pfizer “Pauses” Dosing In DMD Gene Therapy Trial After Patient Death

May 8, 2024

CDER International Post-Market CMC Review Pilot Bearing Fruit, Director Cavazzoni Says; Single Review Platform For All CDER Apps Coming Soon

May 7, 2024

Making Medicare Price Cuts Work: CMS Proposes “Standard” Refund Tied To WAC, But Manufacturers Must Allow For Actual Cost Agreements; 340B Pricing Adds Complexity

May 7, 2024

Prevision Policy Clips | Lykos MDMA (Midomafetamine) Advisory Committee Review Will Test Climate For Psychedelic Treatments

May 7, 2024

FDA Platform Technology Effort Occurring At Opportune Time: Gene Editing Advances May Allow FDA To Be More Ambitious With Pathway

May 6, 2024

Prevision Policy Clips | OCE “Project 5-In-5”: FDA Oncology Center “Crowdsourcing” Five Pragmatic Oncology Trial Ideas

May 6, 2024

Price Negotiation Year 2: Lower Prices And Fewer Meetings? CMS Draft Guidance Tweaks Price-Cutting Process In Anticipation Of More Drugs And Tighter Timelines

May 3, 2024
« First ‹ Prev … 53 54 55 56 57 58 59 60 61 … Next › Last »

Patient-Focused
Drug Development
Database

Access database reports on PFDD meetings.

Log In
LEARN MORE
PrevisionPolicy logo sailboat

What is Prevision Policy?

Prevision Policy provides breaking analysis for biopharma on drug regulation, policy and market access. Our continuous information service gives decision makers actionable insight when they need it most on FDA, CMS, Congress, and how developments in policy impact commercial success.

Prevision Policy was started with the belief that information must be trustworthy, interactive, fast as it is deep, and deliver the bottom line. Strategy is developed in real-time and the biopharma business landscape can change quickly and without warning. Our service has been developed to address those challenges and turn them into opportunities.

To request more information about a company license to the Prevision Policy continuous information service or to get further details about the services we offer, please click here.

Biopharma Congress

Copyright © 2026 Prevision Policy. All Rights Reserved. Privacy Policy